Filtered By:
Specialty: Drugs & Pharmacology
Condition: Brain Tumor

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 50 results found since Jan 2013.

Upregulation of the long non-coding RNA SNHG1 predicts poor prognosis, promotes cell proliferation and invasion, and reduces apoptosis in glioma.
Abstract Long non-coding RNAs (lncRNAs), which are non-coding RNAs with a length above 200 nucleotides, have emerged as novel and important gene expression modulators in carcinogenesis. Recent evidence indicates that the lncRNA small nucleolar RNA host gene 1 (SNHG1) functions as an oncogene in several types of human cancers. However, its function in the development of glioma remains unknown. The aim of this research was to investigate the clinical aspects and biological mechanisms of SNHG1 in glioma. SNHG1 expression was measured in glioma tissues and cell lines by quantitative real-time PCR (qRT-PCR). The associ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - May 11, 2017 Category: Drugs & Pharmacology Authors: Wang Q, Li Q, Zhou P, Deng D, Xue L, Shao N, Peng Y, Zhi F Tags: Biomed Pharmacother Source Type: research

The isoprenoid derivative N6 ‐benzyladenosine (CM223) exerts antitumor effect in glioma patient‐derived primary cells through the mevalonate pathway.
Conclusion and ImplicationsThis biological effect together with structural data on interaction of CM223 with FPPS, gain additional evidence on the correlation of the i6A/CM223 antitumoral activity with FPPS modulation. Because the MVA pathway is becoming an important promising target, CM223 and derivatives should be considered interesting active molecules in antiglioma pharmacological research.
Source: British Journal of Pharmacology - April 18, 2017 Category: Drugs & Pharmacology Authors: Elena Ciaglia, Manuela Grimaldi, Mario Abate, Mario Scrima, Manuela Rodriquez, Chiara Laezza, Roberta Ranieri, Simona Pisanti, Pierangela Ciuffreda, Clementina Manera, Patrizia Gazzerro, Anna Maria D'Ursi, Maurizio Bifulco Tags: RESEARCH PAPER Source Type: research

Nanomedicines for the Treatment of CNS Diseases
AbstractTargeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood –brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, se veral reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regar...
Source: Journal of NeuroImmune Pharmacology - January 31, 2017 Category: Drugs & Pharmacology Source Type: research

Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer
In this study, we tested whether brain endothelial cell-derived exosomes could deliver siRNA across the blood –brain barrier (BBB) in zebrafish. Natural exosomes were isolated from brain endothelial bEND.3 cell culture media and vascular endothelial growth factor (VEGF) siRNA was loaded in exosomes with the assistance of a transfection reagent. While fluorescence-activated cell flow cytometry and immunocy tochemistry staining studies indicated that wild-type exosomes significantly increased the uptake of fluorescence-labeled siRNA in the autologous brain endothelial cells, decreased fluorescence intensity was observed in...
Source: The AAPS Journal - November 22, 2016 Category: Drugs & Pharmacology Source Type: research

MiR-200c and miR-141 inhibit ZEB1 synergistically and suppress glioma cell growth and migration.
CONCLUSIONS: MiR-200c and miR-141 are significantly downregulated in glioma tissues and cell lines and can significantly induce ZEB1 mRNA degradation and suppress ZEB1 protein expression in the cells. ZEB1 is a functional downstream target of miR-200c and miR-141 in inhibiting glioma cell growth and migration. PMID: 27608897 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - September 10, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles
This study aims to investigate the therapeutic effects of intravenous administration of T7 peptide modified core-shell nanoparticles (named T7-LPC/siRNA NPs) on brain tumors. Layer-by-layer assembling of protamine/chondroitin sulfate/siRNA/cationic liposomes followed by T7 peptide modification has been carried out in order to obtain a targeted siRNA delivery system. In vitro cellular uptake experiments demonstrated a higher intracellular fluorescence intensity of siRNA in brain microvascular endothelial cells (BMVECs) and U87 glioma cells when treated with T7-LPC/siRNA NPs compared with PEG-LPC/siRNA NPs. In the co-culture...
Source: International Journal of Pharmaceutics - July 14, 2016 Category: Drugs & Pharmacology Source Type: research

Tangeretin induces cell cycle arrest and apoptosis through upregulation of PTEN expression in glioma cells.
Abstract Tangeretin (TANG), present in peel of citrus fruits, has been shown to various medicinal properties such as chemopreventive and neuroprotective. However, the chemopreventive effect of TANG on glioblastoma cells has not been examined. The present study was designed to explore the anticancer potential of TANG in glioblastoma cells and to investigate the related mechanism. Human glioblastoma U-87MG and LN-18 cells were treated with 45μM concentration of TANG and cell growth was measured by MTT assay. The cell cycle distribution and cell death were measured by flow cytometry. The expression of cell cycle and...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 5, 2016 Category: Drugs & Pharmacology Authors: Ma LL, Wang DW, Yu XD, Zhou YL Tags: Biomed Pharmacother Source Type: research

Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells
Conclusion The siRNA-induced AKT3 and PI3KCA mRNA knockdown in combination with TMZ and BCNU inhibited proliferation and induced apoptosis and autophagy in T98G cells. Thus, knockdown of these genes in combination with TMZ and BCNU may offer a novel therapeutic strategy to more effectively control the growth of human GBM cells, but further studies are necessary to confirm a positive phenomenon for the treatment of GBM.
Source: BioDrugs - February 22, 2016 Category: Drugs & Pharmacology Source Type: research

Insulin-like growth factor 1 specifically up-regulates expression of modifier subunit of glutamate-cysteine ligase and enhances glutathione synthesis in SH-SY5Y cells.
Abstract Glutathione is a key regulator of oxidative balance in all mammals, especially in the central nervous system. The first step of glutathione synthesis is catalyzed by glutamate-cysteine ligase (GCL), which is composed of catalytic and modifier subunits (GCLC and GCLM, respectively). In non-neural cells and tissues, insulin and insulin-like growth factor 1 (IGF-1) have been found to stimulate transcription of GCLC gene. Here we found that treatment of human neuroblastoma SH-SY5Y cells with insulin or IGF-1 increased mRNA level of GCLM, but not of GCLC, in a concentration- and time-dependent manner. In contr...
Source: European Journal of Pharmacology - December 11, 2015 Category: Drugs & Pharmacology Authors: Takahashi S, Hisatsune A, Kurauchi Y, Seki T, Katsuki H Tags: Eur J Pharmacol Source Type: research

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Abstract AIMS: Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM). MiRNAs is considered as an important modulator of drug resistance in many cancers. Here, we aimed to elucidate the relationship between miR-20a, its predicted target genes leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) and TMZ resistance in GBM. MAIN METHODS: Real-time PCR or western blot was used to measure the levels of miR-20a and LRIG1. The cell viability was obtained to investigate the sensitivity of U251 cells and TMZ-resistant U251 (U251/TMZ) cells to TMZ. MiR-20a inhib...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 1, 2015 Category: Drugs & Pharmacology Authors: Wei J, Qi X, Zhan Q, Zhou D, Yan Q, Wang Y, Mo L, Wan Y, Xie D, Xie J, Yang S Tags: Biomed Pharmacother Source Type: research

miR-25 promotes glioma cell proliferation by targeting CDKN1C.
Abstract MicroRNAs (miRNA) have oncogenic or tumor-suppressive roles in the development and growth of human glioma. Glioma development is also associated with alteration in the activities and expression of cell cycle regulators, and miRNAs are emerging as important regulators of cell cycle progression. Here, we show that miR-25 is overexpressed in 91% of examined human glioma tissues and 4 out of 6 human glioma cell lines. MiR-25 increases cell proliferation in two independent glioma cell lines. Ectopic expression of miR-25 was found to reduce CDKN1C protein levels by directly targeting its 3'-untranslated region ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 1, 2015 Category: Drugs & Pharmacology Authors: Zhang J, Gong X, Tian K, Chen D, Sun J, Wang G, Guo M Tags: Biomed Pharmacother Source Type: research

miR-25 promotes glioma cell proliferation by targeting CDKN1C
Publication date: Available online 18 February 2015 Source:Biomedicine & Pharmacotherapy Author(s): Jihong Zhang , Xuhai Gong , Kaiyu Tian , Dongkai Chen , Jiahang Sun , Guangzhi Wang , Mian Guo MicroRNAs (miRNA) have oncogenic or tumor-suppressive roles in the development and growth of human glioma. Glioma development is also associated with alteration in the activities and expression of cell cycle regulators, and miRNAs are emerging as important regulators of cell cycle progression. Here, we show that miR-25 is overexpressed in 91% of examined human glioma tissues and 4 out of 6 human glioma cell lines. MiR-25 ...
Source: Biomedicine and Pharmacotherapy - February 19, 2015 Category: Drugs & Pharmacology Source Type: research

Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation
This study demonstrates the potential of our strategy in glioblastoma therapy. Graphical abstract
Source: International Journal of Pharmaceutics - February 17, 2015 Category: Drugs & Pharmacology Source Type: research

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression
Publication date: Available online 7 February 2015 Source:Biomedicine & Pharmacotherapy Author(s): Junhua Wei , Xuchen Qi , Qitao Zhan , Qingfeng Yan , Yirong Wang , Lianjie Mo , Yingfeng Wan , Dajiang Xie , Jixi Xie , Shuxu Yang Aims Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM). MiRNAs is considered as an important modulator of drug resistance in many cancers. Here, we aimed to elucidate the relationship between miR-20a, its predicted target genes leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) and TMZ resistance in GBM. Main methods Real-...
Source: Biomedicine and Pharmacotherapy - February 8, 2015 Category: Drugs & Pharmacology Source Type: research

Mig-2 attenuates cisplatin-induced apoptosis of human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathways.
Conclusion:Mig-2 significantly attenuates the antitumor action of cisplatin against human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathways. The F3 subdomain of mig-2 is necessary and sufficient for this effect. PMID: 25152024 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - August 25, 2014 Category: Drugs & Pharmacology Authors: Ou YW, Zhao ZT, Wu CY, Xu BN, Song YM, Zhan QM Tags: Acta Pharmacol Sin Source Type: research